Siemens Fonds Invest GmbH Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Siemens Fonds Invest GmbH grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 973.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,345 shares of the medical research company's stock after purchasing an additional 19,356 shares during the period. Siemens Fonds Invest GmbH's holdings in IQVIA were worth $4,195,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after buying an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after buying an additional 712,958 shares in the last quarter. Geode Capital Management LLC grew its position in shares of IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after buying an additional 77,981 shares in the last quarter. Invesco Ltd. grew its position in shares of IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after buying an additional 59,426 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock traded down $0.86 during trading hours on Friday, hitting $140.16. 2,874,682 shares of the company were exchanged, compared to its average volume of 1,577,820. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a 50-day moving average of $150.79 and a 200-day moving average of $180.93. The stock has a market capitalization of $24.25 billion, a price-to-earnings ratio of 18.69, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the prior year, the business earned $2.54 earnings per share. The company's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. UBS Group lowered their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Redburn Partners set a $188.00 price target on IQVIA in a report on Friday, May 23rd. Mizuho lowered their price target on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, Robert W. Baird lowered their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.